Walleye Capital’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$925K Buy
24,300
+21,800
+872% +$919K ﹤0.01% 3541
2026
Q2
$118K Buy
+2,500
New +$61.8K ﹤0.01% 3810
2025
Q4
– Sell
-28,900
Closed -$341K – 4926
2025
Q3
$341K Buy
28,900
+19,600
+211% +$183K ﹤0.01% 2911
2025
Q2
$60.4K Buy
9,300
+2,600
+39% +$17.1K ﹤0.01% 3974
2025
Q1
$39.2K Buy
+6,700
New +$48K ﹤0.01% 3907
2024
Q4
– Sell
-5,200
Closed -$29.6K – 5276
2024
Q3
$29.6K Buy
5,200
+2,400
+86% +$16.7K ﹤0.01% 4744
2024
Q2
$20.2K Buy
+2,800
New +$24.5K ﹤0.01% 5111

Other funds holding DFTX

Walleye Capital's DFTX Position: Q3 2026 in Review

Walleye Capital increased its Definium Therapeutics (DFTX) stake by 35% in Q3 2026, buying an estimated $301K and bringing the position to 27,776 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #3429.

Walleye Capital first reported a position in DFTX in Q2 2024 and has held it in 5 quarters since. 349 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Walleye Capital held 27,776 shares of Definium Therapeutics worth $1.06M as of Q3 2026.
  • Walleye Capital bought 7,133 Definium Therapeutics shares in Q3 2026, an estimated $301K.
  • Definium Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #3429 holding.
  • Walleye Capital first reported a position in Definium Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 349 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.